Hjem
Astrid Børretzens bilde

Astrid Børretzen

Gjesteforsker
  • E-postastrid.borretzen@uib.no
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2023). Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer. Scientific Reports.
  • Vis forfatter(e) (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunology and Immunotherapy.
  • Vis forfatter(e) (2022). PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. Nature Communications. 1-19.
  • Vis forfatter(e) (2021). The epithelial–mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. The journal of pathology. Clinical research. 253-270.
  • Vis forfatter(e) (2019). FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. The journal of pathology. Clinical research. 272-286.
Vitenskapelig foredrag
  • Vis forfatter(e) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC) .
Short communication
  • Vis forfatter(e) (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC. Journal of Clinical Oncology.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Does GEWF solution improve lymph node harvest in colorectal cancer specimens with and without neoadjuvant therapy? Virchows Archiv. 210-211.
Poster
  • Vis forfatter(e) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC).

Se fullstendig oversikt over publikasjoner i CRIStin.